← Eichor
Study identifier: NCT07508761 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

Condition: Advanced Solid Tumor  ·  Sponsor: Nanjing Immunophage Biotech Co., Ltd

PhasePhase 1/Phase 2
Planned participants52
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

This description comes directly from the study's public registry record.

Talk to the study team

jian fei wang, CSO  ·  +86-21-34782827  ·  jfwang@immunophage.com.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Gaobo Tumor HospitalShanghai, PuDongXinQu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07508761